Renhe Pharmacy (000650) Fundamentals 2026 — P/E 20.1x, Revenue Analysis | SniperIQ
Renhe Pharmacy (000650) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥7.4B, trading at ¥5.32 on the SHZ. This SniperIQ fundamentals page covers Renhe Pharmacy's valuation (P/E 20.1x, P/B 1.2x), profitability (net margin 10.0%), revenue (¥3.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Renhe Pharmacy's market cap?
Renhe Pharmacy (000650) has a market capitalization of approximately ¥7.4B, trading at ¥5.32 on the SHZ. Market cap moves with the live share price.
What is Renhe Pharmacy's P/E ratio?
Renhe Pharmacy's trailing twelve-month P/E ratio is 20.1x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Renhe Pharmacy?
Renhe Pharmacy runs a net profit margin of 10.0%, a gross margin of 36.9%, and an operating margin of 17.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Renhe Pharmacy generate?
Renhe Pharmacy reported revenue of ¥3.5B for fiscal year 2025, with net income of ¥393M and earnings per share (EPS) of 0.28. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Renhe Pharmacy pay a dividend?
Renhe Pharmacy offers a trailing dividend yield of about 2.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Renhe Pharmacy financially healthy?
Renhe Pharmacy carries a debt-to-equity ratio of 0.00x and a current ratio of 6.58x, with a market beta of 0.37. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Renhe Pharmacy a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Renhe Pharmacy (000650) the key facts are: market cap ¥7.4B, P/E 20.1x, revenue ¥3.5B, 52-week range 4.85-7.02. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Renhe Pharmacy's full fundamentals live
Get Renhe Pharmacy's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.